Mark J. Gergen

2020 - Poseida Therapeutics

In 2020, Mark J. Gergen earned a total compensation of $1.4M as Chief Executive Officer and President and former Chief Business Officer at Poseida Therapeutics.

Compensation breakdown

Non-Equity Incentive Plan$194,710
Option Awards$804,500
Salary$432,680
Other$9,102
Total$1,440,992

Gergen received $804.5K in option awards, accounting for 56% of the total pay in 2020.

Gergen also received $194.7K in non-equity incentive plan, $432.7K in salary and $9.1K in other compensation.

Rankings

In 2020, Mark J. Gergen's compensation ranked 7,001st out of 13,090 executives tracked by ExecPay. In other words, Gergen earned more than 46.5% of executives.

ClassificationRankingPercentile
All
7,001
out of 13,090
47th
Division
Manufacturing
2,922
out of 5,621
48th
Major group
Chemicals And Allied Products
1,181
out of 2,254
48th
Industry group
Drugs
1,015
out of 1,954
48th
Industry
Biological Products, Except Diagnostic Substances
244
out of 411
41st
Source: SEC filing on April 27, 2022.

Gergen's colleagues

We found two more compensation records of executives who worked with Mark J. Gergen at Poseida Therapeutics in 2020.

2020

Eric Ostertag

Poseida Therapeutics

Chief Executive Officer

2020

Matthew Spear

Poseida Therapeutics

Chief Medical Officer

News

In-depth

You may also like